Stock Market Update

[BRIEFING.COM] The S&P 500 (-0.2%), Nasdaq Composite (+0.2%), and DJIA (-0.6%) are at their best levels of the session shortly after midday. 

Though corporate news flow has been largely overshadowed as energy and geopolitical developments continue to dominate headlines, there are a few notable moves in the mix today. 

Hims & Hers Health (HIMS 22.37, +6.63, +42.12%) is launching higher after confirming a strategic pivot for its U.S. weight-loss business that entails bringing FDA-approved Wegovy and Ozempic (semaglutide) medications onto its telehealth platform and moving away from broadly marketed compounded GLP-1 products, a shift that resolves a legal dispute with Novo Nordisk A/S (NVO 39.71, +1.13, +2.93%) and expands patient access.

This confirmation has immediate financial implications, as it restores a high-visibility revenue stream that had been undercut by regulatory scrutiny and legal challenges, and positions HIMS as a legitimate distribution channel for major branded therapies rather than solely a compounding provider.